Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tryton bifurcation lesion stent

This article was originally published in The Gray Sheet

Executive Summary

Newton, Mass.-based Tryton Medical enrolls one-third of its 30-patient, three-site European feasibility study for the Side-Branch stent, the firm announces Oct. 10. The balloon-expandable stent is used in conjunction with standard coronary stents to treat bifurcation lesions that split into vessels' side branches. The firm hopes to begin a pivotal trial for a drug-eluting version of the product - likely partnering to use a sirolimus derivative - within a year and a half, according to Tryton Chief Technical Officer Richard Davis. The product could reach the U.S. market as early as 2009, he said. According to Tryton, 540,000 procedures for bifurcation lesions are performed each year, representing 20% of all coronary lesions treated. The firm hopes Side-Branch will fill a gap in treatment options to become a new standard of care for these challenging cases...

You may also be interested in...



Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Start-Up Snapshot: Nanomedic’s Electro-Spinning, Portable Wound Care Device

At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.

UsernamePublicRestriction

Register

MT024099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel